What is the 13F Pro Quality Score for ADIL?

13F Pro ranks ADIAL PHARMACEUTICALS, INC. (ADIL) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ADIL's current score at https://13fpro.ai/company/ADIL (free sign-up required for the full ranking).

Where does 13F Pro source ADIL data?

All ADIAL PHARMACEUTICALS, INC. fundamentals and ownership data come directly from SEC EDGAR. ADIAL PHARMACEUTICALS, INC. files with the SEC under CIK 1513525. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ADIL in?

ADIAL PHARMACEUTICALS, INC. (ADIL) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ADIL research updated on 13F Pro?

ADIL's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

ADIAL PHARMACEUTICALS, INC.(ADIL)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1513525 ADIL stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

ADIL Stock Analysis & AI Quality Score

Data updated 2026-07-26

AI stock analysis and institutional research for ADIAL PHARMACEUTICALS, INC. (ADIL), a Healthcare sector company. ADIL is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Top institutional holders of ADIL by reported 13-F value include Stonepine Capital Management, JANE STREET GROUP, CITADEL ADVISORS, based on the most recent SEC filings. ADIL trades on the Nasdaq exchange and files with the SEC under CIK 1513525. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ADIL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ADIAL PHARMACEUTICALS, INC. directly from SEC EDGAR.

✦

Fun facts about ADIAL PHARMACEUTICALS, INC.

Quirks, history, and lore behind ADIL — the kind of stuff that makes a stock memorable.

1
The Basics
A micro-cap biopharmaceutical company listed on Nasdaq, headquartered in Virginia, focused on addiction medicine.
2
The Numbers
With a market cap in the single-digit millions and minimal revenue, this company is firmly in clinical-stage territory — it's betting on science, not sales.
3
The History
Founded in the 2010s, the company was built around a single bold idea: that a low-dose naltrexone-based regimen could help people stop drinking alcohol for good.
4
The Secret
Its lead candidate targets Alcohol Use Disorder (AUD) — one of the most undertreated conditions in the world — using a mechanism tied to the opioid receptor system.
5
The Lore
The company has conducted clinical trials under an FDA Investigational New Drug application, positioning itself in a space where approved treatments are few and far between.
6
The Giveaway
Its ticker is practically a phonetic hint: a tiny pharma firm whose name and symbol both evoke the word "ideal", chasing a cure for alcoholism out of Charlottesville, Virginia.

▶ Think you know your stocks? Play the Daily Ticker

Net Income

Q2 2026

$-52.0M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Net Income

+39.6% YoY

$-8.0MFY 2025

FY22 $-12.7MFY23 $-5.1MFY24 $-13.2MFY25 $-8.0M

Operating Income

+5.9% YoY

$-7.8MFY 2025

FY22 $-10.9MFY23 $-6.9MFY24 $-8.3MFY25 $-7.8M

EPS (Diluted)

+82.5% YoY

$-11.93FY 2025

FY22 $-12.71FY23 $-3.60FY24 $-68.01FY25 $-11.93

Total Assets

+32.3% YoY

$6.7MFY 2025

FY22 $5.7MFY23 $4.7MFY24 $5.0MFY25 $6.7M

Op. Cash Flow

+6.2% YoY

$-6.5MFY 2025

FY22 $-11.2MFY23 $-6.8MFY24 $-6.9MFY25 $-6.5M

Free Cash Flow

—FY 2025

FY22 —FY23 —FY24 —FY25 —

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Income	$-8.0M +39.6%	$-13.2M -157.6%	$-5.1M +59.8%	$-12.7M +34.5%	$-19.4M -78.3%	$-10.9M
Operating Income	$-7.8M +5.9%	$-8.3M -20.3%	$-6.9M +36.6%	$-10.9M +43.7%	$-19.3M -76.5%	$-10.9M
EPS (Diluted)	$-11.93 +82.5%	$-68.01 -1789.2%	$-3.60 +71.7%	$-12.71 -1122.1%	$-1.04	—
Total Assets	$6.7M +32.3%	$5.0M +6.5%	$4.7M -17.4%	$5.7M -23.3%	$7.5M +36.1%	$5.5M
Operating Cash Flow	$-6.5M +6.2%	$-6.9M -1.7%	$-6.8M +39.1%	$-11.2M +6.4%	$-11.9M -56.5%	$-7.6M
Free Cash Flow	—	—	—	—	$-12.0M	—

Get alerted when ADIL's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for ADIAL PHARMACEUTICALS, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ADIL

Stonepine Capital Management, LLC
$1.6M727,563 sh
JANE STREET GROUP, LLC
$82.2K32,119 sh
CITADEL ADVISORS LLC
$75.6K29,547 sh
UBS Group AG
$49.0K19,147 sh
StoneX Group Inc.
$35.7K19,699 sh
GEODE CAPITAL MANAGEMENT, LLC
$31.7K12,393 sh
China Universal Asset Management Co., Ltd.
$20.5K8,000 sh
VANGUARD FIDUCIARY TRUST CO
$15.1K5,879 sh
VANGUARD CAPITAL MANAGEMENT LLC
$14.9K5,831 sh
Manchester Capital Management LLC
$4.9K1,923 sh

Fund	Value	Shares
Stonepine Capital Management, LLC	$1.6M	727,563
JANE STREET GROUP, LLC	$82.2K	32,119
CITADEL ADVISORS LLC	$75.6K	29,547
UBS Group AG	$49.0K	19,147
StoneX Group Inc.	$35.7K	19,699
GEODE CAPITAL MANAGEMENT, LLC	$31.7K	12,393
China Universal Asset Management Co., Ltd.	$20.5K	8,000
VANGUARD FIDUCIARY TRUST CO	$15.1K	5,879
VANGUARD CAPITAL MANAGEMENT LLC	$14.9K	5,831
Manchester Capital Management LLC	$4.9K	1,923

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ADIL on your watchlist

Track score changes the day ADIAL PHARMACEUTICALS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ADIL a good stock to buy?

13F Pro's AI-powered analysis of ADIAL PHARMACEUTICALS, INC. (ADIL) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ADIL are available on the ADIL stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ADIL is classified as a small company.

Which hedge funds own ADIL?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ADIL. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ADIAL PHARMACEUTICALS, INC.'s investment landscape.